key: cord-0833798-fimz8pcc
authors: Medisetty, Mahender Kumar; Patel, Atul; Pujari, Sanjay
title: Letter to the editor on “Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial” by Udwadia Z et al
date: 2021-02-15
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.02.035
sha: ad14ede6d345c54a4527039799ae747881bae38a
doc_id: 833798
cord_uid: fimz8pcc

nan

It is unclear why asymptomatic patients were included in the mild category. This is contrary to widely accepted definitions for categorizing clinical severity of COVID19 (2). Moreover, additional criteria for determining severity especially clinical symptoms are highly subjective and have not been used or validated in any studies of COVID19 treatments. It would have been appropriate to use standard 7-point ordinal scale that has been widely used to assess efficacy of COVID19 therapeutics including remdesivir (3).

It is uncertain how > 95% oxygen saturation (SpO2) was used as criterion for clinical cure as it is likely that all patients had a SpO2 criteria > 94% to align with the mild-moderate definition (2). Additionally, cough relief as a criterion is highly subjective and with open label design may have confounded decision of clinical cure.

Having a range of 40-100 for calculated sample size is surprising and the final sample size has been determined according to regulatory requirements. The analysis violates the ideal intention-to-treat principle (ITT) as 3 patients randomized to FPV arm were excluded and 1 patient because of no available post-baseline evaluation. Excluding patients disturbs the prognostic balance afforded by randomization (4) . The final results would be likely negatively impacted if an ideal ITT analysis performed. About 75% subjects did not have co-morbidities and with mean age of 43 years are expected to have good prognosis. Additionally, periodic assessment of prognostic inflammatory markers is not described. With 4 times higher prevalence of adverse events although self-limiting, the conclusion about safety of FPV needs to be tempered. Finally, information on adherence and missed doses is lacking.

The trial failed to achieve primary endpoint of time to viral clearance. However, conclusions on efficacy are based on multiple secondary outcomes. Validity of analyzing multiple secondary end-points in the absence of significant primary end-point is controversial (5) . Multiplicity adjustments and gate-keeping strategies for secondary endpoints are needed and at best lead to hypothesis generation rather than prove efficacy (6).

In conclusion, we encourage against using expensive FPV as treatment of mild-moderate COVID19 until further evidence is available from well-designed randomized, placebocontrolled clinical trials.

Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial

National Institutes of Health

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial

Understanding the Intention-to-treat Principle in Randomized Controlled Trials

End-point interpretation in clinical trials: the case for discipline

Secondary Efficacy end Points

J o u r n a l P r e -p r o o f